da Wei Liao, MD
Pulmonary Disease · Bethesda, MDNPI 1053379263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,303 of the $309,532 with a category attached, or 77.0%. 60 manufacturers reported payments, led by GSK at 28.4% of the total. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,190 payments — averaging $260.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$88K
- AstraZeneca$65K
- Sanofi$39K
- Regeneron Healthcare Solutions, Inc.$35K
- Grifols USA, LLC$28K
- AbbVie$9K
- plus $46K from 54 others
Across 155 payments — averaging $6410.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$301K
- AstraZeneca$250K
- GSK$153K
- Sanofi US Services Inc.$140K
- United Therapeutics Corporation$79K
- Sanofi$67K
- plus $2K from 1 others
What the payments were for
- Consulting fees$32,19710%
- Speaking & faculty fees$238,30377%
- Travel & lodging$12,9274%
- Food & beverage$25,3758%
- Education$7300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$80,333
- FASENRA$55,665
- TRELEGY ELLIPTA$42,609
- Prolastin-C Liquid$27,624
- ZENPEP$17,410
- NUCALA$12,032
- Prolastin-C$6,697
- ANORO ELLIPTA$3,600
- GLIDE SYSTEM$1,713
- XOLAIR$1,580
- TEZSPIRE$875
- BREZTRI$770
- Yupelri$722
- Da Vinci Surgical System$588
- AIRSUPRA$370
- SYMBICORT$204
- FARXIGA$144
- TOBI Podhaler$136
- Esbriet$125
- Pulmozyme$125
How this compares
$309,532 in reported general payments places this provider in the 95th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 499 | $417,147 |
| OfevNintedanib Esylate | 30 | $391,417 |
| KalydecoIvacaftor | 12 | $320,154 |
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 12 | $308,632 |
| OpsumitMacitentan | 15 | $188,426 |
| ZemairaAlpha-1-Proteinase Inhibitor | 22 | $169,132 |
| EsbrietPirfenidone | 11 | $112,500 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 158 | $111,948 |
| Dupixent SyringeDupilumab | 15 | $84,600 |
| Breo ElliptaFluticasone/Vilanterol | 146 | $80,285 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 132 | $70,865 |
| TezspireTezepelumab-Ekko | 12 | $52,975 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $43,619 |
| Pirfenidone | 29 | $30,544 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $22,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexKalydeco, Trikafta | $163 | $628,78624 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $87,894 | $586,729827 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $730 | $452,997124 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,134 | $188,42615 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $64,581 | $187,737244 claims |
| CSL BehringZemaira | $45 | $169,13222 claims |
| Genentech USA, Inc.Esbriet | $4,183 | $112,50011 claims |
| MerckDulera | $868 | $6,99719 claims |
| PfizerEliquis | $21 | $6,48211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Bethesda
- Kenneth OlivierBethesda$37K
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.